This statistic illustrates the revenue of Ablynx from 2013 to 2017. Ablynx is a Belgian biopharmaceutical company engaged in the discovery and the development of nanobodies. In 2018, the French pharmaceutical company Sanofi acquired Ablynx for 3.9 billion euros. As of 2017, the revenue of Ablynx amounted to roughly 56 million euros, which is less than in the previous year, when Ablynx generated a revenue of approximately 85 million euros.
Revenue of Ablynx from 2013 to 2017
(in 1,000 euros)